EMA/187814/2013

European Medicines Agency decision
P/0084/2013

of 29 April 2013


Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0084/2013

of 29 April 2013


The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency ²,

Having regard to the European Medicines Agency’s decision P/7/2008 issued on 1 February 2008, the decision P/2/2009 issued on 27 January 2009, and the decision P/288/2011 issued on 2 December 2011,

Having regard to the application submitted by medac Gesellschaft für klinische Spezialpräparate mbH on 17 December 2012 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 March 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

---

Has adopted this decision:

**Article 1**

Changes to the agreed paediatric investigation plan for recombinant L-asparaginase, powder for solution for injection or infusion, intravenous use, intramuscular use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

**Article 2**

This decision is addressed to medac Gesellschaft für klinische Spezialpräparate mbH, 3 Fehlandtstrasse, D-20354 – Hamburg, Germany.

Done at London, 29 April 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan
EMEA-000013-PIP01-07-M03

Scope of the application

Active substance(s):
Recombinant L-asparaginase

Condition(s):
Treatment of acute lymphoblastic leukaemia
Treatment of lymphoblastic lymphoma

Pharmaceutical form(s):
Powder for solution for injection or infusion

Route(s) of administration:
Intravenous use
Intramuscular use

Name/corporate name of the PIP applicant:
medac Gesellschaft für klinische Spezialpräparate mbH

Basis for opinion


The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 16 January 2013.
Scope of the modification

Some measures of the Paediatric Investigation Plan were modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 15 March 2013

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of acute lymphoblastic leukaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of acute lymphoblastic leukaemia and lymphoblastic lymphoma

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection or infusion

2.1.4. Measures

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
</tbody>
</table>
| Clinical   | 3                 | Measure 1: Randomised, parallel-group, blinded, single-centre, multiple-dose trial to evaluate pharmacokinetics, pharmacodynamics, activity and safety of recombinant L-asparaginase compared to native E. coli asparaginase in children from 1 year to less than 18 years of age (and adults) with newly-diagnosed acute lymphoblastic leukaemia
Measure 2: Randomised, multi-centre, double-blind trial to evaluate safety, pharmacodynamic equivalence and efficacy of recombinant L-asparaginase compared to native E. coli asparaginase in children from 1 year to less than 18 years of age (and adults) with newly-diagnosed acute lymphoblastic leukaemia
Measure 3: Non-controlled, multi-centre trial to evaluate pharmacodynamics, activity and safety of recombinant L-asparaginase in children from birth to less than 1 year of age with newly-diagnosed acute lymphoblastic leukaemia |
2.2. **Condition: Treatment of lymphoblastic lymphoma**

2.2.1. **Indication(s) targeted by the PIP**

Treatment of lymphoblastic lymphoma

2.2.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From birth to less than 18 years of age

2.2.3. **Pharmaceutical form(s)**

Powder for solution for injection or infusion

2.2.4. **Measures**

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>0</td>
<td>Not applicable.</td>
</tr>
<tr>
<td>Clinical</td>
<td>3</td>
<td>Measure 1: same as for condition treatment of acute lymphoblastic leukaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Measure 2: same as for condition treatment of acute lymphoblastic leukaemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Measure 3: same as for condition treatment of acute lymphoblastic leukaemia</td>
</tr>
</tbody>
</table>

3. **Follow-up, completion and deferral of PIP**

| Concerns on potential long term safety issues in relation to paediatric use: | Yes.                        |
| Date of completion of the paediatric investigation plan:                  | By November 2012.            |
| Deferral for one or more measures contained in the paediatric investigation plan: | No.                         |